• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by NextCure Inc.

    4/25/25 6:08:51 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXTC alert in real time by email
    DEFA14A 1 tm252402d5_defa14a.htm DEFA14A

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A
    (Rule 14a-101)

     

    Proxy Statement Pursuant to Section 14(a)
    of the Securities Exchange Act of 1934

     

    Filed by the Registrant x

     

    Filed by a party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material under §240.14a-12

     

     

    NextCure, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other Than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x  No fee required.
       
    ¨  Fee paid previously with preliminary materials.
       
    ¨  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

    GRAPHIC

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V73330-P30222 NEXTCURE, INC. 9000 VIRGINIA MANOR ROAD SUITE 200 BELTSVILLE, MD 20705 NEXTCURE, INC. 2025 Annual Meeting to Be Held on June 20, 2025 Vote by June 19, 2025 11:59 PM ET You invested in NEXTCURE, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 20, 2025. Vote Virtually During the Meeting* June 20, 2025 3:30 PM ET Virtually at: www.virtualshareholdermeeting.com/NXTC2025 Get informed before you vote View the Notice, Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 6, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V73331-P30222 1. Election of three Class III Directors. Nominees: 1a. David Kabakoff, Ph.D. For 1b. Michael Richman For 1c. Stephen W. Webster For 2. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of NextCure, Inc. for the fiscal year ending December 31, 2025. For 3. Approval, on an advisory basis, of the compensation paid by Company to its named executive officers. For 4. Approval, on an advisory basis, of whether a vote on the compensation of our named executive officers should take place every one year, every two years or every three years. 1 Year 5. Approval of an amendment to our Amended and Restated Certificate of Incorporation that would effect a reverse stock split if, when, and according to a reverse stock split ratio as determined by our Board of Directors. For 6. Approval of one or more adjournments of the Annual Meeting to solicit additional proxies, if necessary. For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting.

    Get the next $NXTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXTC

    DatePrice TargetRatingAnalyst
    11/4/2022Buy → Neutral
    Ladenburg Thalmann
    3/1/2022$16.00Buy
    Ladenburg Thalmann
    11/5/2021$30.00 → $14.00Buy
    Needham
    More analyst ratings

    $NXTC
    Financials

    Live finance-specific insights

    See more
    • NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021

      BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a Virtual Oncology Pipeline Update Event at 4:30 p.m. ET on Monday, November 15, 2021. During the event, NextCure will provide an update on its oncology pipeline, including data presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. The event will also feature Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Directo

      11/1/21 8:00:00 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

      Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025Plan to provide a proof of concept data readout in the first half of 2026Cash of approximately $55.9 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., May 01, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported first quarter 2025 financial results. "With our LNCB74 antibody-drug conjugate ("ADC") program completing coho

      5/1/25 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

      BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET. A live audio webcast will be available through the Investors section of the company's website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative m

      4/4/25 7:00:00 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Provides Business Update and Reports Full Year 2024 Financial Results

      Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2024 financial results. "In 2024 we reprioritized our resources to advance our antibody-drug conjugate ("ADC") program and recently completed cohor

      3/6/25 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Guha Udayan

      3 - NextCure, Inc. (0001661059) (Issuer)

      2/6/25 4:16:36 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sr VP, General Counsel Shaw Kevin G.

      4 - NextCure, Inc. (0001661059) (Issuer)

      2/3/25 6:23:04 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Mayer Timothy

      4 - NextCure, Inc. (0001661059) (Issuer)

      2/3/25 6:22:50 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Leadership Updates

    Live Leadership Updates

    See more
    • NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

      BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4. "We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug c

      4/4/24 7:05:00 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

      BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board. As an accomplished translational tumor immunologist whose research is focused on the role immune cells play in tumor development, Dr. Coussens will support NextCure in its efforts to build and develop its proprietary pipeline of immunomedicines. "We are delighted to have Dr. Coussens join our Scientific Advisory Board, where she will leverage

      10/27/22 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

      BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update. “Our team has worked diligently throughout 2020 to advance our programs despite the difficult environment created by the COVID-19 pandemic. We are thrilled that Dr. Han Myint has recently joined NextCure as our Chief Medical Officer and we are poised to harness his expertise in oncology product development to further advance our product pipe

      3/4/21 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by NextCure Inc.

      SCHEDULE 13G - NextCure, Inc. (0001661059) (Subject)

      5/12/25 12:54:33 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by NextCure Inc.

      10-Q - NextCure, Inc. (0001661059) (Filer)

      5/1/25 4:25:27 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NextCure, Inc. (0001661059) (Filer)

      5/1/25 4:15:24 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NextCure Inc.

      SC 13G/A - NextCure, Inc. (0001661059) (Subject)

      11/14/24 6:59:21 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by NextCure Inc.

      SC 13G/A - NextCure, Inc. (0001661059) (Subject)

      11/13/24 4:06:36 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by NextCure Inc.

      SC 13G - NextCure, Inc. (0001661059) (Subject)

      6/27/24 4:47:26 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NextCure downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded NextCure from Buy to Neutral

      11/4/22 1:03:13 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on NextCure with a new price target

      Ladenburg Thalmann initiated coverage of NextCure with a rating of Buy and set a new price target of $16.00

      3/1/22 7:18:07 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on NextCure with a new price target

      Needham reiterated coverage of NextCure with a rating of Buy and set a new price target of $14.00 from $30.00 previously

      11/5/21 8:42:25 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care